{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T13:19:19Z","timestamp":1755695959579},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,8]]},"DOI":"10.7759\/cureus.61943","type":"journal-article","created":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T12:12:32Z","timestamp":1717848752000},"source":"Crossref","is-referenced-by-count":1,"title":["Assay Interference Causing Persistently Elevated Vancomycin Levels Leading to Treatment Failure and Fatal Outcome"],"prefix":"10.7759","author":[{"given":"Sindhu C","family":"Pokhriyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernestine Faye S","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parjanya K","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad N","family":"Pasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luckencia","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kalpana","family":"Panigrahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1086\/660872","article-title":"Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990-2007","volume":"32","author":"Burton DC","year":"2011","unstructured":"Burton DC, Edwards JR, Srinivasan A, Fridkin SK, Gould CV. Trends in catheter-associated urinary tract infections in adult intensive care units-United States, 1990-2007. Infect Control Hosp Epidemiol. 2011, 32:748-56. 10.1086\/660872","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-004-2157-0","article-title":"Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units","volume":"30","author":"Finfer S","year":"2004","unstructured":"Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med. 2004, 30:589-96. 10.1007\/s00134-004-2157-0","journal-title":"Intensive Care Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.19.2229","article-title":"Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus","volume":"162","author":"Blot SI","year":"2002","unstructured":"Blot SI, Vandewoude KH, Hoste EA, Colardyn FA. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 2002, 162:2229-35. 10.1001\/archinte.162.19.2229","journal-title":"Arch Intern Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01708-10","article-title":"Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens","volume":"55","author":"Roberts JA","year":"2011","unstructured":"Roberts JA, Taccone FS, Udy AA, Vincent JL, Jacobs F, Lipman J. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother. 2011, 55:2704-9. 10.1128\/AAC.01708-10","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/molecules18010204","article-title":"Anti-infectious agents against MRSA","volume":"18","author":"Koyama N","year":"2012","unstructured":"Koyama N, Inokoshi J, Tomoda H. Anti-infectious agents against MRSA. Molecules. 2012, 18:204-24. 10.3390\/molecules18010204","journal-title":"Molecules"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2018.04.004","article-title":"Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients","volume":"32","author":"Bartoletti M","year":"2018","unstructured":"Bartoletti M, Giannella M, Tedeschi S, Viale P. Multidrug-resistant bacterial infections in solid organ transplant candidates and recipients. Infect Dis Clin North Am. 2018, 32:551-80. 10.1016\/j.idc.2018.04.004","journal-title":"Infect Dis Clin North Am"},{"key":"ref7","article-title":"Vancomycin","author":"Patel S","year":"2024","unstructured":"Patel S, Preuss CV, Bernice F. Vancomycin. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2024."},{"key":"ref8","article-title":"Vancomycin","year":"2022","unstructured":"Vancomycin. Drugs and Lactation Database (LactMed\u00ae) [Internet]. National Institute of Child Health and Human Development, Bethesda (MD); 2022."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.2095-4352.2018.07.005","article-title":"Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data [Article in Chinese]","volume":"30","author":"Xu G","year":"2018","unstructured":"Xu G, Chen E, Mao E, Che Z, He J. Research of optimal dosing regimens and therapeutic drug monitoring for vancomycin by clinical pharmacists: analysis of 7-year data [Article in Chinese]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018, 30:640-5. 10.3760\/cma.j.issn.2095-4352.2018.07.005","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxz258","article-title":"Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure","volume":"77","author":"Singer B","year":"2020","unstructured":"Singer B, Stevens RW, Westley BP, Nicolau DP. Falsely elevated vancomycin-concentration values from enzyme immunoassay leading to treatment failure. Am J Health Syst Pharm. 2020, 77:9-13. 10.1093\/ajhp\/zxz258","journal-title":"Am J Health Syst Pharm"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2279","article-title":"Falsely elevated vancomycin concentrations in a patient not receiving vancomycin","volume":"39","author":"Tsoi V","year":"2019","unstructured":"Tsoi V, Bhayana V, Bombassaro AM, Tirona RG, Kittanakom S. Falsely elevated vancomycin concentrations in a patient not receiving vancomycin. Pharmacotherapy. 2019, 39:778-82. 10.1002\/phar.2279","journal-title":"Pharmacotherapy"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00220-d","article-title":"Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure","volume":"672","author":"Najjar TA","year":"1995","unstructured":"Najjar TA, al-Dhuwailie AA, Tekle A. Comparison of high-performance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure. J Chromatogr B Biomed Appl. 1995, 672:295-9. 10.1016\/0378-4347(95)00220-d","journal-title":"J Chromatogr B Biomed Appl"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai MP","year":"2014","unstructured":"Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014, 77:50-7. 10.1016\/j.addr.2014.05.016","journal-title":"Adv Drug Deliv Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03147-14","article-title":"Optimizing the clinical use of vancomycin","volume":"60","author":"\u00c1lvarez R","year":"2016","unstructured":"\u00c1lvarez R, L\u00f3pez Cort\u00e9s LE, Molina J, Cisneros JM, Pach\u00f3n J. Optimizing the clinical use of vancomycin. Antimicrob Agents Chemother. 2016, 60:2601-9. 10.1128\/AAC.03147-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.20.3.311-316.1984","article-title":"Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay","volume":"20","author":"Pfaller MA","year":"1984","unstructured":"Pfaller MA, Krogstad DJ, Granich GG, Murray PR. Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin Microbiol. 1984, 20:311-6. 10.1128\/jcm.20.3.311-316.1984","journal-title":"J Clin Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160760","article-title":"Novel approach to vancomycin level monitoring: impact of a multidisciplinary monitoring system on timing of vancomycin levels","volume":"75","author":"Peyko V","year":"2018","unstructured":"Peyko V, Friedman-Jakubovics M. Novel approach to vancomycin level monitoring: impact of a multidisciplinary monitoring system on timing of vancomycin levels. Am J Health Syst Pharm. 2018, 75:121-6. 10.2146\/ajhp160760","journal-title":"Am J Health Syst Pharm"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/IJCIIS.IJCIIS_39_18","article-title":"Assessment of acute kidney injury in neurologically and traumatically injured intensive care patients receiving large vancomycin doses","volume":"8","author":"May CC","year":"2018","unstructured":"May CC, Erwin BL, Childress M, et al.. Assessment of acute kidney injury in neurologically and traumatically injured intensive care patients receiving large vancomycin doses. Int J Crit Illn Inj Sci. 2018, 8:194-200. 10.4103\/IJCIIS.IJCIIS_39_18","journal-title":"Int J Crit Illn Inj Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/1735-5362.301337","article-title":"A simple and validated HPLC method for vancomycin assay in plasma samples: the necessity of TDM center development in Southern Iran","volume":"15","author":"Ghasemiyeh P","year":"2020","unstructured":"Ghasemiyeh P, Vazin A, Zand F, Azadi A, Karimzadeh I, Mohammadi-Samani S. A simple and validated HPLC method for vancomycin assay in plasma samples: the necessity of TDM center development in Southern Iran. Res Pharm Sci. 2020, 15:529-40. 10.4103\/1735-5362.301337","journal-title":"Res Pharm Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/237253-assay-interference-causing-persistently-elevated-vancomycin-levels-leading-to-treatment-failure-and-fatal-outcome","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T12:12:38Z","timestamp":1717848758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/237253-assay-interference-causing-persistently-elevated-vancomycin-levels-leading-to-treatment-failure-and-fatal-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.61943","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,8]]}}}